Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a fatty liver fuel Alzheimer's? new scan aims to find out

NCT ID NCT06453915

Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detect brain inflammation linked to liver disease. The goal is to develop a practical imaging tool to study how liver inflammation might contribute to Alzheimer's disease and related dementias.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG and 18F-DPA-714 (imaging tracers)
What this could lead to
If successful, this imaging method could help researchers study how liver inflammation affects brain health, potentially pointing toward new ways to prevent or treat Alzheimer's disease.
What could go wrong
This is a very small, early-phase study focused on developing a measurement tool, not a treatment. The method may not prove reliable or useful in larger, more diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants \>=18 years age * Participants who have or have planned a liver biopsy as: * standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or * as part of another Clinical Trials study for MASH, or * standard of care prior to undergoing bariatric surgery * Liver biopsy needs to be within 6 months of planned study-related imaging * Ability to provide informed consent. Exclusion Criteria: * History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease. * Uncontrolled claustrophobia * Body weight \>225 kg due to limitations of the scanner bed * Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available) * Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only. * Prisoners * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives. * Pre-existing neurodegenerative disorders and dementia * Significant history of major skull concussion or repetitive head trauma * Currently on anticoagulant therapy * Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatohepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Positron emission tomography

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UC Davis EXPLORER Molecular Imaging Center

    RECRUITING

    Sacramento, California, 95816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.